Evidence map›Paper›PMID 31331387›Full record

ArticleJournal of medical case reports2019

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.

Sheila Chiesi, Sebastiano Rizzardo, Daniela Piacentini, Giorgia Be, Emanuela Lattuada, Evelina Tacconelli, Massimiliano Lanzafame

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sheila ChiesiInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy. sheilachiesi@gmail.com.ORCID http://orcid.org/0000-0002-0108-0722
Sebastiano RizzardoInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
Daniela PiacentiniInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
Giorgia BeInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
Emanuela LattuadaInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
Evelina TacconelliInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
Massimiliano LanzafameInfectious Diseases Department, University Hospital of Verona, Piazzale L.A. Scuro, Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentifying the most appropriate antiretroviral regimen for pregnant women with Human Immunodeficiency Virus (HIV-1) infection can be challenging, mainly due to pregnancy-related physiological alterations which can significantly reduce maternal drug plasma concentration. We would like to report our experience as it consists of an unusual case of low plasmatic concentration of antiretroviral drugs despite regimen intensification in a HIV-positive pregnant woman. It also underlines the need for accurate monitoring and treatment adjustment in pregnant women with Human Immunodeficiency Virus (HIV). CASE PRESENTATION: A 26-year-old Brazilian woman with HIV-1 infection attending our out-patient clinic presented with low plasmatic concentration of antiretroviral drugs and persistent detectable viral load despite regimen intensification during pregnancy. Trough plasma concentrations of dolutegravir and darunavir were measured by validated liquid chromatography-mass spectrometry. At 23 weeks of gestation it showed a lower value than expected in non-pregnant adults, compared to a normal level of plasma concentration measured at 10 weeks after delivery. Our patient and the baby had no regimen-related adverse effects.

conclusionsPhysiological changes during pregnancy can affect pharmacokinetics and reduce a mother's bioavailability of antiretroviral drugs, potentially altering their pharmacological activity. A personalized treatment and a careful follow-up are hence mandatory for this key population.

Indexed as

DarunavirDolutegravirFemaleHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsHumansOxazinesPiperazinesPregnancyPregnancy Complications, InfectiousPyridonesViral LoadYoung AdultDarunavirDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesCtroughDarunavirDolutegravirHIV-1PharmacokineticsPregnancy

Identifiers

PMID31331387
PMCPMC6647129
OpenAlexW2963142720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.